We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Search
Filters
9068 Results

Congress Abstract

Acute toxicity of hypo- and conventionally-fractionated radiosensitised bladder radiotherapy
Authors:

Robert Huddart1, Shaista Hafeez2, Abdullahi Omar3, Ananya Choudhury4, Alison Birtle5, Isabel Syndikus6, Benjamin Hindson7, Mohini Varughese8, Ann Henry9, Duncan McLaren10, Farshad Foroud11, Amanda Webster12, Helen McNair13, Anna Tolentino3, Luke Webster3, Hannah Gribble3, Lara Philipps3, Ashok Nikapota14, Omi Parikh15, Roberto Alonzi16, Rana Mahmood17, Serena Hilman18, Yvonne Rimmer19, Clare Griffin20, Emma Hall20

1Institute of Cancer Research , Clinical Academic Radiotherapy, London, United Kingdom; 2Institute of Cancer Research, Radiotherapy and Imaging, London, United Kingdom; 3Institute of Cancer Research, Clinical Trials and Statistics Unit, London, United Kingdom; 4The Christie NHS Foundation Trust, Translational Radiobiology, Manchester, United Kingdom; 5Lancashire Teaching Hospitals NHS Trust, Cancer Oncology, Lancashire, United Kingdom; 6The Clatterbridge Cancer Centre, Department of Radiotherapy, Liverpool, United Kingdom; 7Canterbury District Health Board , Department of Oncology Services, Christchurch, United Kingdom; 8Royal Devon & Exeter NHS Foundation Trust, Department of Oncology, Exeter, United Kingdom; 9Leeds Teaching Hospitals NHS Trust, Division of Cancer Studies and Pathology, Leeds, United Kingdom; 10NHS Lothian , · Department of Oncology , Edinburgh, United Kingdom; 11Austin Health, Radiation Oncology, Austin, Australia; 12Radiotherapy Trials Quality Assurance (RTTQA), N/A, London, United Kingdom; 13Institute of Cancer Research, Division of Radiotherapy and Imaging, London, United Kingdom; 14Brighton and Sussex University Hospitals NHS Trust, Clinical Oncology, Brighton, United Kingdom; 15Lancashire Teaching Hospitals NHS Trust, Oncology, Burnley , United Kingdom; 16Hillingdon Hospitals NHS Foundation Trust, Clinical Oncology, London, United Kingdom; 17East Suffolk and North Essex NHS Foundation Trust, Oncology, Colchester, United Kingdom; 18University Hospitals Bristols NHS Foundation Trust, Clinical Oncology, Bristol, United Kingdom; 19Cambridge University Hospitals NHS Foundation Trust, Department of Oncology, Cambridge, United Kingdom; 20Institute of Cancer Research, Clinical Trial and Statistics Unit, London, United Kingdom

Show Affiliations
2021
Oral
ESTRO 2021

Congress Abstract

Automated proton treatment planning with robust optimization and dose volume constraints
Authors: Taasti|, Vicki(1)*[vicki.taasti@maastro.nl];Hong|, Linda(1);Deasy|, Joseph(1);Zarepisheh|, Masoud (1);
(1)Memorial Sloan Kettering Cancer Center, Medical Physics, New York, USA;
Show Affiliations
2020
Poster
ESTRO 2020

Congress Abstract

Estimating the dosimetric effects of intrafraction motion: the role of surface imaging
Authors: Kügele|, Malin(1)*[malin.kugele@skane.se];
(1)Skåne University Hospital, Department of Hematology- Oncology and Radiation Physics, Lund, Sweden;
Show Affiliations
2020
ESTRO 2020

Congress Abstract

The 100 most cited articles in prostate cancer brachytherapy: A bibliometric study
Authors: Zhao|, Hongfu(1)*[79590076@qq.com];Cheng|, Guanghui(1);Wu|, Ning(1);He|, Mingyuan(1);Zhao|, Zhipeng(1);Zhang|, Ning(1);
(1)China-Japan Union Hospital of Jilin University, Radiation Oncology, Changchun, China;
Show Affiliations
2020
Poster
ESTRO 2020

Journal Article

Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method
Authors: Ellie Tsiamis, Jeremy Millar, Siddhartha Baxi, Martin Borg, Paolo De Ieso, Hany Elsaleh, Farshad Foroudi, Braden Higgs, Tanya Holt, Jarad Martin, Kim Moretti, David Pryor, Marketa Skala, Sue Evans
2018
Radiotherapy and Oncology

Congress Abstract

Artificial Intelligence based planning of HDR prostate brachytherapy: first clinical experience.
Authors:

Danique Barten1, A. Bouter2, N. van Wieringen1, B.R. Pieters1, K.A. Hinnen1, G.H. Westerveld1, S.C. Maree2, M.C. van der Meer1, T. Alderliesten3, P.A.N. Bosman2, Y. Niatsetski4, A. Bel1

1Amsterdam UMC, University of Amsterdam, Radiation Oncology, Amsterdam, The Netherlands; 2Centrum Wiskunde & Informatica, Life Sciences and Health Group, Amsterdam, The Netherlands; 3LUMC, Radiation Oncology, Leiden, The Netherlands; 4Elekta, -, Veenendaal, The Netherlands

Show Affiliations
2021
Poster Discussion
ESTRO 2021

Webcast

Excellent antitumor activity of SBRT and FOLFIRINOX in patients with pancreatic cancer
Authors: Joost Nuyttens
2020
ESTRO 2020 - Online congress

Journal Article

The population benefit of radiotherapy for cervical cancer: Local control and survival estimates for optimally utilized radiotherapy and chemoradiation
Authors: T.P. Hanna, J. Shafiq, G.P. Delaney, M.B. Barton
2015
Radiotherapy and Oncology

Congress Abstract

Sexual rehabilitation and management of erectile dysfunction after treatment for male pelvic cancer
Authors: Incrocci|, Luca(1)*[l.incrocci@erasmusmc.nl];
(1)Erasmus Medical Center Rotterdam, Department of Radiation Oncology, Rotterdam, The Netherlands;
Show Affiliations
2020
ESTRO 2020

Congress Abstract

Experience with Dutch National Indication Protocol_v1 model-based selection of proton therapy in HNC
Authors: Tambas|, Makbule(1)*[makbule_tambas@hotmail.com];van den Hoek|, Johanna G.M.(1);Kierkels|, Roel G.J. (1);Scandurra|, Dan(1);Wolters|, Atje-Marleen(1);Mulder|, Dennis(1);Oldehinkel|, Edwin(1);Meijer|, Tineke W.H.(1);Both|, Stefan(1);Steenbakkers|, Roel J.H.M.(1);Langendijk|, Johannes A.(1);
(1)University of Groningen- University Medical Center Groningen, Radiation Oncology, Groningen, The Netherlands;
Show Affiliations
2020
Oral
ESTRO 2020
*:*